TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis C$16.35 -0.16 (-0.97%) As of 09/19/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Cipher Pharmaceuticals Stock (TSE:CPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$16.17▼C$16.5450-Day RangeC$12.05▼C$16.7952-Week RangeC$10.61▼C$18.36Volume32,866 shsAverage Volume27,945 shsMarket CapitalizationC$415.19 millionP/E Ratio35.54Dividend YieldN/APrice TargetC$14.75Consensus RatingModerate Buy Company Overview Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States. Read More Cipher Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreCPH MarketRank™: Cipher Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingCipher Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Downside RiskCipher Pharmaceuticals has a consensus price target of C$14.75, representing about 9.8% downside from its current price of C$16.35.Amount of Analyst CoverageCipher Pharmaceuticals has received no research coverage in the past 90 days.Read more about Cipher Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cipher Pharmaceuticals is 35.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Cipher Pharmaceuticals is 35.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 80.50.Price to Book Value per Share RatioCipher Pharmaceuticals has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCipher Pharmaceuticals does not currently pay a dividend.Dividend GrowthCipher Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CPH. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for CPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.24% of the stock of Cipher Pharmaceuticals is held by institutions.Read more about Cipher Pharmaceuticals' insider trading history. Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPH Stock News HeadlinesCipher Pharmaceuticals’ Record Earnings Driven by NatrobaAugust 13, 2025 | msn.comCipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record RevenueAugust 8, 2025 | theglobeandmail.comWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.September 21 at 2:00 AM | SmartAsset (Ad)CPH - Cipher Pharmaceuticals Inc Key Metrics - MorningstarJune 24, 2025 | morningstar.comMEarnings call transcript: Cipher Pharmaceuticals misses Q1 2025 EPS expectationsMay 11, 2025 | uk.investing.comEarnings call transcript: Cipher Pharmaceuticals Q4 2024 sees stock surgeMarch 21, 2025 | uk.investing.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 ResultsMarch 19, 2025 | theglobeandmail.comCipher Pharmaceuticals Inc.'s (TSE:CPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?March 17, 2025 | uk.finance.yahoo.comSee More Headlines CPH Stock Analysis - Frequently Asked Questions How have CPH shares performed this year? Cipher Pharmaceuticals' stock was trading at C$14.32 at the start of the year. Since then, CPH stock has increased by 14.2% and is now trading at C$16.35. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) released its quarterly earnings data on Thursday, August, 10th. The company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.01. The business had revenue of $7.10 million for the quarter, compared to the consensus estimate of $7.46 million. Cipher Pharmaceuticals had a net margin of 59.92% and a trailing twelve-month return on equity of 17.93%. Read the conference call transcript. How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Enbridge (ENB), Bellatrix Exploration (BXE), Crescent Point Energy (CPG), Manulife Financial (MFC), Surge Energy (SGY) and Toronto-Dominion Bank (TD). Company Calendar Last Earnings8/10/2023Today9/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Cipher PharmaceuticalsC$14.75 High Price TargetC$17.00 Low Price TargetC$12.50 Potential Upside/Downside-9.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)C$0.46 Trailing P/E Ratio35.54 Forward P/E Ratio12.67 P/E GrowthN/ANet IncomeC$11.41 million Net Margins59.92% Pretax MarginN/A Return on Equity17.93% Return on Assets7.90% Debt Debt-to-Equity Ratio41.22 Current Ratio2.00 Quick Ratio2.67 Sales & Book Value Annual SalesC$47.59 million Price / Sales8.72 Cash FlowC$4.63 per share Price / Cash Flow3.53 Book ValueC$3.96 per share Price / Book4.13Miscellaneous Outstanding Shares25,394,000Free FloatN/AMarket CapC$415.19 million OptionableNot Optionable Beta0.56 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (TSE:CPH) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.